We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Mologic and BioSure Partner on COVID-19 Antibody Self-Test

Mologic and BioSure Partner on COVID-19 Antibody Self-Test content piece image
Credit: rawpixel
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Mologic Ltd, a developer of diagnostic technologies, has announced that it has joined forces with BioSure, experts in self-testing, to produce a COVID-19 antibody self-test.

By combining Mologic’s independently verified COVID-19 lateral flow test with BioSure’s design, the companies have created a self-test for COVID-19 that can be used without any training being required. The test is designed to be easy to use, requires only a fraction of a drop of blood and gives the user their own result in just 10 minutes.

The BioSURE COVID-19 Antibody Self-Test will be ready for mass production at the beginning of June. It will be available to the UK and global markets and will also be available to be directly purchased by end-consumers.

Building on a longstanding partnership, materials for all of Mologic’s COVID-19 diagnostics are being supplied to the Institut Pasteur de Dakar in Senegal who will manufacture tests for the African continent at their flagship facility diaTROPiX in Dakar.

Since March, alongside Liverpool School of Tropical Medicine (LSTM) and St George’s, University of London, leading laboratories across the world have partnered with Mologic to rapidly iterate, improve, and validate the Company’s COVID-19 diagnostic prototypes and independently assess performance.